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ABSTRACT
The antimicrobial peptide database (APD, http://
aps.unmc.edu/AP/main.php) has been updated and
expanded. It now hosts 1228 entries with 65 anti-
cancer, 76 antiviral (53 anti-HIV), 327 antifungal and
944 antibacterial peptides. The second version of
our database (APD2) allows users to search peptide
families (e.g. bacteriocins, cyclotides, or defensins),
peptide sources (e.g. fish, frogs or chicken), post-
translationally modified peptides (e.g. amidation,
oxidation, lipidation, glycosylation or D-amino
acids), and peptide binding targets (e.g. membra-
nes, proteins, DNA/RNA, LPS or sugars). Statistical
analyses reveal that the frequently used amino acid
residues (>10%) are Ala and Gly in bacterial pep-
tides, Cys and Gly in plant peptides, Ala, Gly and
Lys in insect peptides, and Leu, Ala, Gly and Lys in
amphibian peptides. Using frequently occurring
residues, we demonstrate database-aided peptide
design in different ways. Among the three peptides
designed, GLK-19 showed a higher activity against
Escherichia coli than human LL-37.
INTRODUCTION
The antimicrobial peptide ﬁeld is growing rapidly in
response to the demand for novel antimicrobial agents
(1–5). To promote the research, education and informa-
tion exchange in the ﬁeld, we established the multifunc-
tional antimicrobial peptide database (APD) in 2003 and
published a brief description in the database issue of
Nucleic Acid Research in 2004 (6). Although there are
other databases (7–14), APD has been widely utilized
by users around the world (15000 web hits per year)
(15–17). APD is a general database dedicated to antimi-
crobial peptides from all biological sources, ranging from
bacteria, plants, to animals, including humans. The
database collects only ‘mature and active’ peptides
(<100 amino acid residues), rather than a mixture of
mature and precursor proteins. Furthermore, the peptides
in APD are classiﬁed based on their biological activities
such as anticancer, antiviral, antifungal and antibacterial,
allowing users to readily obtain a list of peptides of special
interest to them. In addition, the database provides statis-
tical information for all listed peptides, or a group of
peptides with desired properties such as anticancer.
Finally, the database has interfaces for both peptide pre-
diction and peptide design. APD also provides ‘Links’ that
allow users to access other databases dedicated to antimi-
crobial peptides.
Since the publication of the ﬁrst version of APD in
2004, a signiﬁcant number of antimicrobial peptides
have been discovered at both the gene and protein
levels. Therefore, it is proper to include the newly identi-
ﬁed members into APD. In total, more than 700 addi-
tional peptides have been registered. To meet the new
requirements of the ﬁeld as well as based on users’ feed-
back, we have constructed additional search capabilities
for the database. These include peptide families, sources,
posttranslational modiﬁed peptides, and peptide-binding
targets. Finally, we illustrate that novel antimicrobial pep-
tides can be designed with the aid of APD. Among the
three peptides designed, one of them showed a higher
activity against Escherichia coli than human LL-37. Here
we brieﬂy describe the new features and ﬁndings of the
second version of APD (hereinafter referred to as
APD2). For new users, please also read our original article
(6) or read ‘About’ (a brief guide to APD2) online, as the
previously described functions and ﬁndings are not reiter-
ated here.
DATABASE UPDATE
To facilitate database update and maintenance, we pur-
chased the NAVICAT 8 software (PremiumSoft
CyberTech Limited, Hong Kong) and solved the compat-
ibility problem with our database by writing additional
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peptide parameters should the original peptide sequence
have been corrected, updated or completely replaced. By
September 2008, APD2 possesse 1228 peptide entries.
Relative to the original 525 entries (6), the total number
of antimicrobial peptides in APD2 has been more than
doubled. Among them, the number of antibacterial pep-
tides increased from 498 to 944 (i.e. by 90%), antifungal
peptides from 155 to 327 (by 111%), antiviral peptides
from 28 to 76 (by 171%) and anticancer peptides from
18 to 65 (by 261%). It appears that the interest in devel-
oping antiviral and anticancer peptides on the basis of
naturally occurring antimicrobial peptides is growing
(18–20).
NEW FEATURES ADDED
The ‘name’ ﬁeld of APD2 has been expanded signiﬁcantly
through extensive information registration. Peptide syno-
nyms such as LL-37 and LL37 are included. This feature
should beneﬁt the ongoing eﬀort in standardizing the
nomenclature of antimicrobial peptides from amphibians
(21,22). Because both the old and new names of the same
peptides are entered, APD2 will facilitate the transition
from the old to the new names.
Not all antimicrobial peptides have complete amino
acid sequences. A list of peptides with incomplete amino
acid sequences can be viewed by entering the letter string
‘BWQ’ into the name ﬁeld followed by clicking on the
‘search’ button. Currently, APD2 collects 18 such entries.
APD2 allows the search for peptides from a particular
life form by using common names: ‘bacteria, plant, ants,
ﬁsh, cow, insect, crabs, toad and frog’ (actual words for
search), to list just a few. For example, when the word
‘frog’ was searched in the name ﬁeld, 398 peptides (32%
in APD2) appeared, consistent with the notion that
amphibians are an important source for natural antimi-
crobial peptides (1,21,22). Similarly, we found 203 pep-
tides from plants, 118 from insects and 112 from
bacteria. Therefore, the majority of the naturally occur-
ring antimicrobial peptides collected in APD2 are origi-
nated from animals. To advance our understanding of the
structure-activity relationships of antimicrobial peptides
as a basis for peptide design, a select set of synthetic pep-
tide derivatives were also collected. After update, the data-
base contains 38 synthetic peptides (3% in APD2). Most
of the synthetic peptides have known 3D structures, deter-
mined primarily by solution NMR spectroscopy (23,24).
In total, there are 160 peptides (152 by NMR and eight by
X-ray diﬀraction) with known 3D structures (70 origin-
ally). As long as the structural coordinates are deposited
with the Protein Data Bank (PDB) (25), the structure of a
particular peptide can be viewed directly by clicking on the
PDB link provided in APD2 for each peptide entry.
In addition, ‘peptide families’ can be searched, also via
the name ﬁeld. When the word ‘cyclotide’ (small circular
proteins from plants) (19) was entered, 126 peptides
appeared. Likewise, we found 131 defensins and 51 cathe-
licidins when such words were searched.
To allow for the search for ‘chemically modiﬁed anti-
microbial peptides’, a coding system was created by start-
ing with XX. Thus, phosphorylation, lipidation,
glycosylation, C-terminal amidation, peptide cyclization,
oxidation and D-amino acids are represented by a set of
unique letter strings (Table 1). Such modiﬁcations are
described in the ‘Additional Info’ ﬁeld so that the unmo-
diﬁed peptide sequence can be entered into the database.
In total, 259 chemically modiﬁed peptides were found
when XX was used to search in the name ﬁeld. Among
them, 135 peptides are cyclic, 113 peptides are C-termin-
ally amidated (XXA), seven peptides are oxidized (XXO),
and nine peptides contain D-amino acids (XXD). The
number of D-amino acid residues in a peptide is indicated
by an Arabic number after the code XXD. This annota-
tion is very important since some antimicrobial peptides
such as gassericin A (APD2 entry 766) and reutericin 6
(APD2 entry 930) share the same amino acid sequence and
diﬀer only in the number of D-amino acids. Note that the
actual numbers of chemically modiﬁed peptides in the
database will vary due to continued updating of our
database.
It is now accepted that ‘molecular targets’ of antimicro-
bial peptides are not restricted to bacterial membranes and
can be other molecules as well (1–5). To enable the search
for peptide targets, we also deﬁned a set of unique letter
strings (starting BB) for diﬀerent targets such as proteins,
nucleic acids, sugars and metal ions (Table 1) and entered
such information into the database. A typical example is
human LL-37, which is capable of binding to a variety of
molecules such as proteins (represented by BBPP), DNA
(BBD) and lipopolysaccharides or LPS (BBL) (reviewed in
reference 15). In addition, the peptide is able to form oli-
gomers by itself (BBB) in aqueous solutions upon increase
in peptide concentrations or salts. Likewise, the string
BBBm is coined as an indicator for peptide oligomeriza-
tion in membrane environments. A further description of
the interactions between antimicrobial peptides and diﬀer-
ent targets is given in the ﬁeld of ‘Additional Info’ (e.g. see
entry 310 for LL-37). This change will enrich the key
information on biochemical and physical property, activ-
ity, 3D structure and mechanism of action of each anti-
microbial peptide in APD2.
It is also useful to search for peptides that target a
particular microbe by using the letter ‘Z’. When ‘ZZH’
was used to search, 53 anti-HIV peptides appeared. A
further classiﬁcation of the peptide sources was also
Table 1. Letter keys for searching antimicrobial peptides with chemical
modiﬁcation and peptide binding targets in APD2
Code Chemical modiﬁcation Code Binding target
XXA C-end amidation BBMm Membranes
XXC Cyclization BBB Peptide aggregation
XXO Oxidation BBPP Proteins/enzymes
XXP Phosphorylation BBN RNA/DNA
XXD D-amino acids BBS Sugars
XXG Glycosylation BBL Lipopolysaccharides (LPS)
XXL Lipidation BBII Metal ions (e.g. Fe
3+)
D934 Nucleic Acids Research, 2009, Vol. 37, Databaseissuemade: ZZHa, anti-HIV peptides from animals (14 entries);
ZZHb, anti-HIV peptides from bacteria (three entries);
ZZHp, anti-HIV peptides from plants (24 entries, mainly
cyclotides); ZZHh, anti-HIV peptides from humans (six
entries); ZZHs, anti-HIV peptides from chemical synthesis
(six entries). Additional letters can be appended to indi-
cate the binding targets of HIV-active peptides. Such a
feature is useful for users to choose a peptide template
for engineering anti-HIV peptides by mutagenesis (20).
Likewise, future database annotations will allow users to
search for peptides with toxicity against a particular drug-
resistant bacterial strain (ZZB), parasites (ZZP), or certain
type of cancer cells (ZZC).
FREQUENTLY USED RESIDUES, MOTIFS AND
APPLICATIONS IN PEPTIDE DESIGN
Frequentlyusedaminoacidresiduesinantimicrobialpeptides
The search capability for peptide sources, families, and
activities can be combined with the peptide analysis
tools in APD2. A statistical analysis was conducted for
a group of peptides from bacteria, plants, insects, and
frogs. These life kingdoms were chosen because of a rela-
tively large pool of peptides (>100 members) (Table 2).
While the details are provided in the Supplementary table,
the percentages for the 20 amino acids in each group of
peptides from the four kingdoms are plotted in Figure 1.
We deﬁne a residue in antimicrobial peptides as ‘fre-
quently used’ if its percentage is 10% or greater. Thus,
residues Ala and Gly are most abundant in bacterial pep-
tides (dark blue line in Figure 1); residues Cys and Gly are
more common in plant peptides (red line); residues Ala,
Gly and Lys are frequently occurring in insect peptides
(light blue line); and residues Leu, Ala, Gly and Lys
have percentages higher than 10% in frog peptides
(green line). A summary of these results is given in
Table 2. It is notable that residue Gly is highly used in
antimicrobial peptides from all the four kingdoms. In con-
trast, residue Met is rarely used (<1.5%). Interestingly,
cationic Lys is preferred over Arg in all the kingdoms.
In particular, residues Arg and Tyr are rarely used
(<1%) in frog peptides. The reasons for these observa-
tions remain to be elucidated in the future. However, the
lists of highly used residues derived from antimicrobial
peptides from diﬀerent kingdoms (Table 2) contain struc-
tural information. The abundance in residue Cys in plant
peptides suggests that disulﬁde bonds (related to b-sheets)
are common, rendering the peptide structure more stable
(19). Indeed, the percentage of the Cys residue is also high
in peptides with known b-sheet structures. Likewise, the
frequently used residues from frogs (Leu, Ala, Gly and
Lys) have the strong tendency to adopt an amphipathic
helix. Interestingly, a search of APD2 for antimicrobial
peptides with known helical structures followed by statis-
tical analysis of the 170 peptides revealed the same set of
frequently occurring residues.
Database-aided peptide design
The frequently used residues identiﬁed in each kingdom
(Table 2) may be applied to peptide design in diﬀerent
ways. First, new antimicrobial peptides can be designed
based on ‘templates derived from naturally occurring anti-
microbial peptides’. Recently, we have identiﬁed the smal-
lest antibacterial peptide, KR-12 (Table 3), from human
LL-37 (26). Using KR-12 as the template, we designed
KL-12 (Table 3) by converting all hydrophobic residues
to leucines and all charged and hydrophilic residues to
lysines. Unfortunately, antibacterial assays using the stan-
dard microdilution method (27) found that KL-12 was
inactive against Gram-negative bacteria such as E. coli
K12 or Gram-positive bacteria such as methicin-resistant
Staphyloccocus aureus (MRSA) USA-300 until 160mM.
However, this method may be successful with other
more active peptide templates. Second, new antimicrobial
Figure 1. The percentages of the 20 amino acid residues in antimicro-
bial peptides discovered from bacteria, plants, frogs and insects. The
cutoﬀ line at 10% deﬁnes frequently occurring residues (10% or
greater). A summary of the frequently used residues is listed in Table 2.
Table 3. Minimal inhibitory concentrations (mm) of a few peptides
designed based on frequently occurring residues and their combinations














MULTI-18 GLFDAAKKIVGKLITSLN 80 >160
aData from reference 26. The region in the LL-37 sequence that corre-
sponds to KR-12 is underlined.
Table 2. Frequently used amino acid residues in naturally occurring







Bacteria 112 A, G
Plants 203 C, G b-Sheet
Insects 118 A, G,K
Frogs 398 A, G,K ,L a-Helix
The bold face is letter ‘G’ indicates amino acid is common in all life
kingdom.
Nucleic Acids Research, 2009,Vol. 37,Database issue D935peptides can be designed by ‘combining database-derived
peptide motifs’, consisting of frequently used residues
(Table 2). Using the motifs consisting of only residues
Gly, Leu and Lys, a second peptide was designed. GLK-
19 (Table 3) was found to be active against E. coli and also
weakly active against MRSA. Third, new peptides can be
designed based on ‘amino acid percentages obtained from
statistical analysis of antimicrobial peptides’ from a spe-
ciﬁc kingdom or peptide family (e.g. see Supplementary
table). Thus, a third peptide was designed in three steps. (i)
The amino acid composition for MULTI-18 was obtained
by multiplying the percentage of each residue with the
total number of residues (18 here) in the target peptide.
Thus, we obtained 2 Gly, 2 Ala, 3 Leu, 3 Lys, 2 Ile, 1 Phe,
1 Asp, 1 Val, 1 Thr, 1 Ser and 1 Asn residues based on the
statistical values obtained. (ii) We searched peptide motifs,
consisting of these residues and found that sequence com-
binations such as GLFD, AAK, KIV, GKL, ITS and LN
all exist in at least ﬁve peptides in APD2. (iii) Multiple
peptides can be obtained by combining the above motifs.
We only designed one peptide by following the amphi-
pathic pattern for helical peptides. The resulting peptide
MULTI-18 showed a low activity against E. coli.
Although we only designed three peptides, one of the pep-
tides (GLK-19) was found to have a higher antibacterial
activity against E. coli than human LL-37 (Table 3).
Therefore, our results prove the principle that APD2 is a
useful tool for peptide design. In the previous version of
our database (6), we already observed that antimicrobial
peptides with toxic eﬀects on mammalian cells are more
hydrophobic. That ﬁnding, consistent with the results
from experiments (28), should be useful in improving
the therapeutic indexes of the designed peptides such as
GLK-19 in the next step.
SUMMARY AND DATABASE AVAILABILITY
Our database update increased the number of antimicro-
bial peptides from 525 to 1228. This increase should
improve the reliability of the results from the statistical
interface. New search capabilities such as peptide families,
peptide sources and anti-HIV activity have been created
via extensive information annotations and registration for
peptide entries. In addition, both chemically modiﬁed pep-
tides and molecular targets of antimicrobial peptides can
be searched. In combination with the statistical interface,
we found that frequently used amino acid residues in anti-
microbial peptides diﬀer in diﬀerent kingdoms (Table 2).
Using the frequently occurring residues from amphibian
peptides, we demonstrate that the APD2 ﬁndings are
useful in peptide design.
In conclusion, this update illustrates nicely the ﬂexibility
of our original database that allows expansion in both
database functions and the scope of peptides to be col-
lected. While the database update and developments
continue, you are welcome to email us your comments,
suggestions, or corrections for which we are grateful.
APD2 can be accessed at the same website http://
aps.unmc.edu/AP/main.php.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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